Regeneron said on Monday its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in ...

Regeneron shares fell nearly 18% on Friday after its experimental drug for patients with a type of lung condition commonly ...

Shares in both companies were lower after one study met the primary goal and a second missed its main target in their drug ...

Regeneron Pharmaceuticals said on Monday a combination of its experimental drug and Novo Nordisk's obesity drug Wegovy helped ...

Regeneron Pharmaceuticals said on Monday its experimental weight-loss drug combination helped preserve muscle mass in a ...

Me (OTC:MEHCQ) faces a second auction after a $305M bid challenges Regeneron's (REGN) initial bid for its assets. Read more ...

Regeneron Pharma stock has been in a persistent downtrend for over 280 days. Here's why you should avoid REGN.

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

Regeneron’s shares have declined nearly 17% following the failure of the company’s Dupixent follow-up itepekimab.

Regeneron and Sanofi face setbacks as itepekimab stumbles in phase 3. Click here to read why I believe SNY and REGN stocks ...

A key decision by the bankruptcy judge could help with protecting consumer data, write Diane Lourdes Dick and Anya Prince.

Regeneron isn’t the only Big Pharma to spot potential in Hansoh’s obesity pipeline. Merck & Co. ended last year paying $112 ...